Pagine dedicate alla Neurologia per l'aggiornamento dei Colleghi e per informazioni sulle nuove terapie e descrizioni di patologie rivolte in modo comprensibile ai pazienti

                                                                                          Dott. Carlo Sebastiano Tadeo
                                                                                                Specialista Neurologia

Pergolide riduce i tic nella sindrome di Tourette

 

                           Iscrivetevi alle Newsletter                   

                                             Newsletter  

 

 

 Novità dai principali congressi e pubblicazioni scientifiche 

Journals neurology

Per prenotare una visita neurologica

Servizio Traduzione

Medline

Congressi e convegni

Malattie neurologiche

Ictus
Sclerosi Multipla
Alzheimer
Parkinson
Neuropatie ereditarie
Cefalee

 

 

Pubblicità e links utili

 

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.

 

 

www.ilneurologo.com - Candidato al Premio Web Italia 2003

Tourette’s syndrome improvement with pergolide in a randomized, double-blind, crossover trial


D. L. Gilbert, MD; G. Sethuraman, PhD; L. Sine, MS; S. Peters, BA; F. R. Sallee, MD, PhD

From the Children’s Hospital Medical Center and Departments of Neurology (Dr. Gilbert) and Psychiatry (Drs. Sethuraman and Sallee and S. Peters), University of Cincinnati, OH; and the Department of Psychiatry (L. Sine), the Medical University of South Carolina, Charleston, SC.

NEUROLOGY 2000;54:1310-1315

[Click here for reference links. (27 references linked.)]

Article abstract—Objective: To determine whether pergolide, a mixed D1-D2-D3 dopamine agonist, is efficacious and safe in the treatment of children with Tourette’s syndrome. Background: Neuroleptics, which block dopamine transmission, are currently used for treatment of children with severe tics, but major side effects and limited efficacy reduce clinical utility. Prior open-label reports of pergolide suggest potential benefit. Methods: The authors enrolled 24 children age 7 to 17 years with Tourette’s disorder, chronic motor tic disorder, or chronic vocal tic disorder by Diagnostic and Statistical Manual of Mental Disorders (4th ed.) criteria, plus severity criteria on the Yale Global Tic Severity Scale (YGTSS) of 20, in a double-blind, placebo-controlled, crossover study. Children were randomized to receive either placebo or up to 300 g/day pergolide for the first 6-week treatment period, with a 2-week placebo washout, followed by crossover to the alternate treatment. The primary outcome measure was tic severity assessed by YGTSS. Results: Compared with placebo treatment, pergolide treatment was associated with significantly lower YGTSS scores (42.0 ± 20.4 versus 23.5 ± 18.7; F = 12.0, df = 1, 17, p = 0.0011). No patient had a serious adverse event and pergolide was well tolerated. Conclusions: In this randomized, placebo-controlled, crossover trial, pergolide appeared to be a safe and efficacious treatment for Tourette’s syndrome in children.

 

Per ulteriori informazioni, contattare:

Il Neurologo con voi
Via Copernico 59/a Milano 20125
Tel: 03332699103
Posta elettronica: tadeo@ilneurologo.com

            

Spazio pubblicitario libero

 

Inviare a tadeo@ilneurologo.com un messaggio di posta elettronica contenente domande o commenti su questo sito Web.
Aggiornato il: 27 February 2001